CASIA OpenIR  > 中国科学院分子影像重点实验室
18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma
Kong,Ziren1,2; Lin,Yusong3,10; Jiang,Chendan1; Li,Longfei3; Liu,Zehua3; Wang,Yuekun1; Dai,Congxin1; Liu,Delin1,2; Qin,Xuying5,9; Wang,Yu1; Liu,Zhenyu4,8; Cheng,Xin2; Tian,Jie4,6,7,8; Ma,Wenbin1
Source PublicationCancer Imaging
Corresponding AuthorCheng,Xin( ; Tian,Jie( ; Ma,Wenbin(
AbstractAbstractBackgroundThe methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) promoter has emerged as a favorable independent prognostic and predictive biomarker in glioma. This study aimed to build a radiomics signature based on 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) for noninvasive measurement of the MGMT promoter methylation status in glioma.MethodsOne hundred and seven pathology-confirmed primary diffuse glioma patients were retrospectively included and randomly assigned to the primary (n?=?71) or validation cohort (n?=?36). The MGMT promoter methylation status was measured by pyrosequencing. A total of 1561 radiomics features were extracted from the three-dimensional region of interest (ROI) on the standard uptake value (SUV) maps that were generated from the original 18F-FDG PET data. A radiomics signature, a clinical signature and a fusion signature that combined the clinical and radiomics features together were generated. The performance of the three signatures was evaluated by receiver operating characteristic (ROC) curve analysis, and the patient prognosis was stratified based on the MGMT promoter methylation status and the signature with the best performance.ResultsFive radiomics features were selected to construct the radiomics signature, and displayed the best performance with area under the receiver operating characteristic (ROC) curve (AUC) reaching 0.94 and 0.86 in the primary and validation cohorts, respectively, which outweigh the performances of clinical signature and fusion signature. With a median follow-up time of 32.4?months, the radiomics signature stratified the glioma patients into two risk groups with significantly different prognoses (p?=?0.04).Conclusions18F-FDG-PET-based radiomics is a promising approach for preoperatively evaluating the MGMT promoter methylation status in glioma and predicting the prognosis of glioma patients noninvasively.
KeywordRadiomics FDG PET MGMT promoter methylation Glioma Prognosis
WOS IDBMC:10.1186/s40644-019-0246-0
PublisherBioMed Central
Citation statistics
Document Type期刊论文
Corresponding AuthorCheng,Xin; Tian,Jie; Ma,Wenbin
Recommended Citation
GB/T 7714
Kong,Ziren,Lin,Yusong,Jiang,Chendan,et al. 18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma[J]. Cancer Imaging,2019,19(1).
APA Kong,Ziren.,Lin,Yusong.,Jiang,Chendan.,Li,Longfei.,Liu,Zehua.,...&Ma,Wenbin.(2019).18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma.Cancer Imaging,19(1).
MLA Kong,Ziren,et al."18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma".Cancer Imaging 19.1(2019).
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Kong,Ziren]'s Articles
[Lin,Yusong]'s Articles
[Jiang,Chendan]'s Articles
Baidu academic
Similar articles in Baidu academic
[Kong,Ziren]'s Articles
[Lin,Yusong]'s Articles
[Jiang,Chendan]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Kong,Ziren]'s Articles
[Lin,Yusong]'s Articles
[Jiang,Chendan]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.